{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:56Z","timestamp":1794047516073,"version":"4.8.0"},"reference-count":36,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Five hundred and thirty-five patients (median age 12.2 years; range, 8 months to 18 years; N=303 males, N=232 females) diagnosed with chronic myeloid leukemia (CML) in chronic phase were registered in the International Registry of Childhood CML (clinicaltrials gov. Identifier: NCT01281735). Clinical signs of leukostasis or bleeding were observed in 16.5% and 20% of the patients, respectively. The spleen was palpable in 76% of patients with a median of 9 cm (range, 1-32) below the costal margin. The median leukocyte count was 222x109\/L (interquartile range, 95-353). First-line therapy consisted of imatinib in 482 children. Among them, 40% remained on imatinib with a median follow-up 3.8 years (95% confidence interval [CI]: 3.2- 4.3 years); 3.1% died and 3.9% progressed to advanced-phase disease. The overall survival rate at 36 months was 97.4% (95% CI: 95-99%). Progression-free survival rate at 3-years was 97.1% (95% CI: 94.9-99.2%), 91.7% (95% CI:84.5-98.3%) and 72.0% (95% CI: 59-87.9%) in the Eutos Long-Term Survival (ELTS) low-, intermediate-, and high-risk group, respectively (P log rank &lt;0.001). Pediatric CML is characterized by bulky disease (large splenomegaly, high leukocyte counts) and the ELTS score can identify children with the poorest outcome.<\/jats:p>","DOI":"10.3324\/haematol.2025.288283","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:56:48Z","timestamp":1761206208000},"page":"1280-1288","source":"Crossref","is-referenced-by-count":3,"title":["Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML"],"prefix":"10.3324","volume":"111","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"De Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalet Meral","family":"G\u00fcnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"De Moerloose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Luesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Molines","family":"Honrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Ampatzidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dworzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Lausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Borisevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Kong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kolenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Jakovljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roula","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Durocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"87688","doi-asserted-by":"crossref","unstructured":"Millot F, Traore P, Guilhot J. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005; 116(1):140-143.","DOI":"10.1542\/peds.2004-2473"},{"key":"87689","doi-asserted-by":"crossref","unstructured":"Millot F, Baruchel A, Guilhot J. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol. 2011; 29(20):2827-2832.","DOI":"10.1200\/JCO.2010.32.7114"},{"key":"87690","doi-asserted-by":"crossref","unstructured":"Suttorp M, Schulze P, Glauche I. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia. 2018; 32(7):1657-1669.","DOI":"10.1038\/s41375-018-0179-9"},{"key":"87691","doi-asserted-by":"crossref","unstructured":"Baccarani M, Deininger MW, Rosti G. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013; 122(6):872-884.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"87692","doi-asserted-by":"crossref","unstructured":"Sokal JE, Baccarani M, Tura S. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985; 66(6):1352-1357.","DOI":"10.1182\/blood.V66.6.1352.bloodjournal6661352"},{"key":"87693","doi-asserted-by":"crossref","unstructured":"Pfirrmann M, Clark RE, Prejzner W. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020; 34(8):2138-2149.","DOI":"10.1038\/s41375-020-0931-9"},{"key":"87694","doi-asserted-by":"crossref","unstructured":"Schoch C, Schnittger S, Bursch S. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002; 16(1):53-59.","DOI":"10.1038\/sj.leu.2402329"},{"key":"87695","doi-asserted-by":"crossref","unstructured":"Hughes T, Deininger M, Hochhaus A. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108(1):28-37.","DOI":"10.1182\/blood-2006-01-0092"},{"key":"87696","doi-asserted-by":"crossref","unstructured":"Branford S, Cross NC, Hochhaus A. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006; 20(11):1925-1930.","DOI":"10.1038\/sj.leu.2404388"},{"key":"87697","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"87698","doi-asserted-by":"crossref","unstructured":"Cross NCP, Ernst T, Branford S. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023; 37(11):2150-2167.","DOI":"10.1038\/s41375-023-02048-y"},{"key":"87699","doi-asserted-by":"crossref","unstructured":"Soverini S, Colarossi S, Gnani A. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on chronic myeloid leukemia. Clin Cancer Res. 2006; 12(24):7374-7379.","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"87700","doi-asserted-by":"crossref","unstructured":"Millot F, Maledon N, Guilhot J, G\u00fcne\u015f AM, Kalwak K, Suttorp M. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. Eur J Cancer. 2019; 115:17-23.","DOI":"10.1016\/j.ejca.2019.03.020"},{"key":"87701","doi-asserted-by":"crossref","unstructured":"Hoffmann VS, Baccarani M, Hasford J. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015; 29(6):1336-1343.","DOI":"10.1038\/leu.2015.73"},{"key":"87702","doi-asserted-by":"crossref","unstructured":"Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol. 1997; 96(1):111-116.","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x"},{"key":"87703","doi-asserted-by":"crossref","unstructured":"Jain P, Kantarjian P, Patel KP. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors Blood. 2016; 127(10):1269-1275.","DOI":"10.1182\/blood-2015-10-674242"},{"key":"87704","doi-asserted-by":"crossref","unstructured":"Gore L, Kearns PR, de Martino ML. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018; 36(13):1330-1338.","DOI":"10.1200\/JCO.2017.75.9597"},{"key":"87705","doi-asserted-by":"crossref","unstructured":"Hijiya N, Maschan A, Rizzari C. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019; 134(23):2036-2045.","DOI":"10.1182\/blood.2019000069"},{"key":"87706","doi-asserted-by":"crossref","unstructured":"Brivio E, Pennesi E, Willemse ME. Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the phase I part of study ITCC054\/COG AAML1921. J Clin Oncol. 2023; 42(7):821-831.","DOI":"10.1200\/JCO.23.00897"},{"key":"87707","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Lauseker M, Saussele S. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017; 31(11):2398-2406.","DOI":"10.1038\/leu.2017.253"},{"key":"87708","doi-asserted-by":"crossref","unstructured":"Hoffmann VS, Baccarani M, Hasford J. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry Leukemia. 2017; 31(3):593-601.","DOI":"10.1038\/leu.2016.246"},{"key":"87709","doi-asserted-by":"crossref","unstructured":"Zhang XS, Gale RP, Li ZY. Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy Leukemia. 2022; 36(8):2042-2049.","DOI":"10.1038\/s41375-022-01616-y"},{"key":"87710","doi-asserted-by":"crossref","unstructured":"Guilhot F, Rigal-Huguet F, Guilhot J. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia. 2021; 35(8):2332-2345.","DOI":"10.1038\/s41375-020-01117-w"},{"key":"87711","doi-asserted-by":"crossref","unstructured":"Castagnetti F, Di Raimondo F, De Vivo A. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. Am J Hematol. 2017; 92(1):82-87.","DOI":"10.1002\/ajh.24591"},{"key":"87712","doi-asserted-by":"crossref","unstructured":"Geelen IGP, Thielen N, Janssen JJWN. Treatment outcome in a population-based, \u2018real-world\u2019 cohort of patients with chronic myeloid leukemia. Haematologica. 2017; 102(11):1842-1849.","DOI":"10.3324\/haematol.2017.174953"},{"key":"87713","doi-asserted-by":"crossref","unstructured":"Millot F, Guilhot J, Baruchel A. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood. 2014; 124(15):2408-2410.","DOI":"10.1182\/blood-2014-05-578567"},{"key":"87714","doi-asserted-by":"crossref","unstructured":"Roy Moulik N, Keerthivasagam S, Pandey A. Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort. Br J Haematol. 2024; 204(4):1249-1261.","DOI":"10.1111\/bjh.19251"},{"key":"87715","doi-asserted-by":"crossref","unstructured":"Giona F, Putti MC, Micalizzi M. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol. 2015; 170(3):398-407.","DOI":"10.1111\/bjh.13453"},{"key":"87716","doi-asserted-by":"crossref","unstructured":"Shimada H, Watanabe A, Ito M. A Multicenter, prospective study for pediatric chronic myeloid leukemia in chronic phase: the JPLSG CML-08 Study. Blood. 2021; 138:3605.","DOI":"10.1182\/blood-2021-154335"},{"key":"87717","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Larson RA, Guilhot F. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10):917-927.","DOI":"10.1056\/NEJMoa1609324"},{"key":"87718","doi-asserted-by":"crossref","unstructured":"Pfirrmann M, Baccarani M, Saussele S. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016; 30(1):48-56.","DOI":"10.1038\/leu.2015.261"},{"key":"87719","doi-asserted-by":"crossref","unstructured":"Zhang XS, Gale RP, Huang XJ, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?. Leukemia. 2021; 36(2):482-491.","DOI":"10.1038\/s41375-021-01387-y"},{"key":"87720","doi-asserted-by":"crossref","unstructured":"Millot F, Guilhot J, Suttorp M. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica. 2017; 102(10):1704-1708.","DOI":"10.3324\/haematol.2017.170035"},{"key":"87721","doi-asserted-by":"crossref","unstructured":"Millot F, Ampatzidou M, Roy Moulik N. Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations. Leukemia. 2025; 39(4):779-791.","DOI":"10.1038\/s41375-025-02543-4"},{"key":"87722","doi-asserted-by":"crossref","unstructured":"Millot F, Suttorp M, Ragot S. Discontinuation of imatinib in children with chronic myeloid leukemia: A study from the International Registry of Childhood CML. Cancers. 2021; 13(16):4102-4109.","DOI":"10.3390\/cancers13164102"},{"key":"87723","doi-asserted-by":"crossref","unstructured":"Shima H, Kada A, Tanizawa A. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia. Pediatr Blood Cancer. 2022; 69(8):e29699.","DOI":"10.1002\/pbc.29699"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12957\/78971","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12957\/79864","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12957\/78971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:06Z","timestamp":1794046206000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.288283","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}